Fair enough, KJT was asking for input re his valuations and discounts applied. But no one offered any variations on his numbers to demonstrate why a TO of say $50 was valid in the DCF model that NEU will be using in case of a TO. After perhaps 4 phase 2 trials, FDA guidance on phase 3 requirements, Daybue sales increasing and new territories opening up. As well as initial works on 4/6 new indications.
Neuren Media and Analyst Coverage, page-1149
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |